antithrombotic therapy was commenced
within 48 hours of onset of symptoms. There was no significant difference in early outcomes between therapies in
either study. However, in one trial, the post hoc analysis
analyzed the incidence of neurologic deterioration at
10 days and found that low-molecular-weight heparin
therapy was associated with a signiÔ¨Åcant decrease in
ischemic stroke progression (5%) compared with aspirin

(12.7%)